<DOC>
	<DOCNO>NCT02652585</DOCNO>
	<brief_summary>Using theTEMA ( test system development medication alcoholism ) show , naltrexone administration reduces willingness perform work alcohol infusion laboratory experiment .</brief_summary>
	<brief_title>Validation Test System Development Medications Alcoholism</brief_title>
	<detailed_description>Objective study show laboratory alcohol self-administration method predict therapeutic potential new compound reduce relapse alcohol-dependent patient . The 'TEMA '' translate several animal behavioral paradigm alcohol self-administration correspond human experiment . We investigate opiate antagonist Naltrexone , whose anti-relapse effect well document , reference drug validation . Main objective : With TEMA ( test system development medication alcoholism ) show , naltrexone administration reduces willingness perform work alcohol infusion laboratory experiment . Secondary objective : - administration naltrexone comparison placebo lead reduction alcohol crave real-life drinking - administration naltrexone comparison placebo lead reduction CDT-Level - administration naltrexone comparison placebo lead change perception subjective alcohol effect - effectiveness naltrexone predict A118G polymorphism OPRM1 - administration naltrexone change baseline alcohol-induced ability motor inhibition - administration naltrexone change baseline alcohol-induced regional cerebral perfusion - administration naltrexone change baseline alcohol-induced cerebral rest state activity - change alcohol effect brain activity induce naltrexone comparison placebo correlate effect naltrexone willingness work alcohol self-administration</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>male female volunteer age 25 55 year least weekly alcohol consumption medium risk level accord WHO Timeline Followback Interview last 45 day average amount alcohol 41 g/day ( men ) 31 g/day ( woman ) least 6 day alcohol consumption &gt; 100 g/day ( men ) 75 g/day ( woman ) least 4 non consecutive alcohol abstinent day last 45 day least 1 drinking day full week screen visit 1 6 abstinent day week visit 1 demand treatment risky alcohol consumption write consent Information history hypersensitivity alcohol one use medicinal product , ingredient medicinal product similar chemical structure participation another clinical trial within last 4 week inclusion addiction disorder , allow subject ass character importance possible consequence clinical trial pregnant breastfeed woman woman capable bearing child , except woman fulfil follow criterion : postmenopausal ( 12 month natural amenorrhoea 6 month amenorrhoea Serum FSH &gt; 40 ml U/ml ) post operative ( 6 week ovariectomy side without hysterectomy ) regular correct use contraceptive method error Quote &lt; 1 % per year ( example implant , depot injection , oral contraceptive , IUP ) . It recognize combined oral contraception contrast pure progesterone compound failure rate &lt; 1 % . Hormone IUDs Pearl Index 1 % safe copper IUDs . sexual abstinence vasectomy Partner evidence participant expect comply protocol ( example lack compliance ) current previous alcohol substance dependence accord DSMIV ( exception : tobacco dependence ) current previous treatment alcohol , example addiction advisory centre , selfhelp group , detoxification treatment current previous disease , alcohol infusion cause clinically relevant hazard ( e. g. pancreatitis , liver cirrhosis ) current plan intake opiate analgesic current psychiatric treatment intake psychiatric drug suffer psychiatric disease require treatment history suicide attempt CIWAScore &gt; 5 Screening ( alcohol withdrawal scale ) history symptom alcohol withdrawal , epileptic seizure delirium routine laboratory Parameters , indicate relevant liver , pancreas kidney injury , acute infection , anaemia lack vitamin ( ASAT , ALAT &gt; twofold standard screening , gammaGT , lipase &gt; threefold standard , CRP &lt; 15 mg/l , creatin indicate moderate renal insufficiency ( eGFR &lt; 60 ml/min ) , leucocytes &gt; 12000/Âµl , haemoglobin &lt; 7,5 mmol/l ( men ) 6,5 mmol/l ( woman ) , MCV &gt; 100 fl ) Body weight &gt; 130 kg drug screen urine : positive screening opiate , cannabis , cocaine , amphetamine , benzodiazepine positive visit 1 opiate positive twice visit 1 cannabis , cocaine , amphetamine , benzodiazepine breath alcohol concentration screen &gt; 0,00 g/kg twice &gt; 0,00 g/kg visit 1 unsuitable fMRT ( e. g. cardiac pacemaker , claustrophobia ) specific contraindication naltrexone : acute hepatitis severe acute liver disease severe kidney disease rare hereditary galactose intolerance , Lapplactasedeficiency Glucosegalactosemalabsorption</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Alcoholism</keyword>
	<keyword>alcohol self-administration</keyword>
</DOC>